These hub genes identified in our study have implications for the response to immune checkpoint inhibitors therapy (PRKDC) and offer potential prognostic markers (CUL1, VAV2), presenting a novel avenue or additional treament for thyroid cancer therapeutics. Here, CUL1 is linked to thyroid cancer.